Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

ibo for the treatment of adult ALL from the U.S. Food and Drug Administration. Marqibo has also received orphan drug designation from the European Medicines Evaluation Agency in adult ALL.

About Marqibo(R) (vincristine sulfate liposomes injection)

Marqibo is a novel, targeted, Optisomal(TM) formulation of vincristine, a widely-used chemotherapy, which has shown promising anti-cancer activity in patients with ALL, non-Hodgkin's lymphoma, Hodgkin's disease, and melanoma in several clinical trials. Vincristine is approved by the U.S. Food and Drug Administration as a single agent and in combination regimens for the treatment of hematologic malignancies such as lymphomas and leukemias. Vincristine, a microtubule inhibitor, kills cancer cells when they enter a very specific point in the cell cycle, and its efficacy is concentration- and exposure duration-dependent. Marqibo is designed to enhance the penetration and retention of vincristine at sites of active cancer and facilitate dose-intensification compared to standard vincristine formulations. Unlike regular vincristine, Marqibo is dosed based on patient body surface area without the need to limit the dose to avoid early dose-limiting neurotoxicities.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq: HNAB) is a biopharmaceutical company dedicated to developing new, differentiated cancer therapies designed to improve and enable current standards of care. The Company has two lead product candidates that target large markets and are in pivotal and/or proof-of-concept clinical trials. Marqibo is being developed to treat lymphoid cancers such as ALL and lymphomas. Menadione topical lotion is a first-in-class compound being developed as a prevention and/or treatment of skin toxicity associated with epidermal growth f
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 29, 2011 ViewRay™, Inc., a privately held ... MRI-guided radiotherapy at the annual meeting of the ... – 4 in Miami Beach, Florida, with software ... radiation therapy system is being developed to feature ...
... 29, 2011 Medical Alarm Concepts Holding, Inc. (OTCQB: ... for capital that will be used to accelerate corporate ... first fully-monitored medical alarm system that allows users to ... third of this private investment group funding has already ...
Cached Medicine Technology:ViewRay Demonstrates Potential Therapy Applications for MRI-Guided Radiation at ASTRO 2011 2Medical Alarm Concepts Receives Growth Capital Injection and Commitment for Future Funding 2Medical Alarm Concepts Receives Growth Capital Injection and Commitment for Future Funding 3
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... Previous studies have shown that proliferation of endogenous ... damage to neurons and axons. From the perspective ... from Sun Yat-sen University in China observed the ... neural precursor cell proliferation and expression of basic ... the rat brain on the infarct side. The ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... that can provide primary care for low-income patients ... and insurance companies while improving patient health, researchers ... suggests that health clinics that avoid costs associated ... by lowering hospital admission rates and emergency room ... Penn State Altoona. , The researchers estimated ...
(Date:4/22/2014)... risk of pregnancy among women using a newer method ... 10 times greater over a 10-year period than using ... researchers at Yale University and UC Davis has found. ... Contraception , the study found the higher risk ... the brand name Essure. , "This study provides ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... Laparoscopic cholecystectomy (LC) has rapidly substituted traditional cholecystectomy, ... of cholelithiasis. ,Bile duct injury (BDI) remains the ... recent survey, published in the October issue of ... BDI has become more frequent with LC. ...
... one of the most neurotoxic plants in western Mediterranean ... are known to be neurotoxic.// This shrub produces a ... the berries. ,Ingestion of few fruits similar ... seizures, coma and apnea. ,A recent paper ...
... issue of the Academy of General Dentistry's monthly newsmagazine, ... and is the most important factor in the prevention ... of the population. ,"Flossing every 24 hours to ... said Gordon Isbell, DMD, MAGD, spokesperson for the Academy ...
... colleagues from Toyama University, Japan have found that supplementation ... children’s behavior. //Researchers have found that Docosahexaenoic acid (DHA), ... an important component of cell membranes of the retina ... boys who have lower concentrations of DHA in blood. ...
... beer and alcohol increases the risk of colorectal tumours, ... to a study. // ,The study, conducted by ... University, Stony Brook, New York, was meant to examine ... of significant colorectal neoplasia in a screening population., ...
... products that would help women protect themselves from sexually ... any form that is convenient to use such as ... microbicides will enable women to negotiate condom use or ... would also help avoid unwanted pregnancies, according to experts.,With ...
Cached Medicine News:Health News:Higher incidence of bile duct injury during laparoscopic cholecystectomy 2Health News:Poisoning by fruits similar to blackberries 2Health News:Alcohol Drinking Affects Risk Of Colorectal Tumours 2
A software program for simple, efficient pulse oximetry analysis, which enables easy viewing, analysis and report generation for pulse rate and SpO 2 ....
... ,MARS Technology is the next generation in ... addition to our current family of "digital ... of new technological breakthroughs in signal processing. ... signal resulting in superior performance during challenging ...
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... The Nellcor N-20PA Handheld Pulse Oximeter is ... The durable construction of the N-20PA has ... temperatures and conditions it has even ... is conveniently portable for spot check measurements ...
Medicine Products: